Lucerna, Inc.

Lucerna, Inc. is addressing the $9 billion early-stage drug discovery failure problem with an RNA-focused approach. Traditional protein-centric methods target only 0.05% of the human genome, whereas our technology unlocks access to over 70%—vastly expanding drug discovery opportunities. Our mission is to develop faster, cost-efficient tools that make disease-modifying RNAs both “visible” and “druggable,” increasing the chances of treating diseases with unmet medical needs. Lucerna offers innovative RNA-focused research reagents powered by our proprietary fluorogenic RNA (Spinach™) technology. Our robust, user-friendly imaging solutions provide real-time RNA visualization in live cells—enabling seamless integration across microscopy, flow cytometry, and high-content imaging platforms. Further, our hit screening platforms deliver cellular drug activity insights in high-throughput format, reducing costs and shortening hit discovery and validation timelines. Designed specifically for RNA-focused drug discovery, Lucerna’s innovative products address critical gaps in early-stage drug discovery. With faster workflows and unmatched versatility, our solutions support every phase of the RNA life cycle, from cellular studies to high-throughput drug discovery. Whether for imaging, screening, or industrial applications, our products empower scientists with precision, speed, and innovation.